H. Lundbeck A/S
Total number of voting rights and share capital in H. Lundbeck A/S as of 31 May 2015

DGAP-News: H. Lundbeck A/S

2015-06-02 / 02:46

---------------------------------------------------------------------

In accordance with Section 6 of the Danish Statutory Order on Issuers'
Disclosure Obligations, H. Lundbeck A/S is required to publish the total number
of voting rights and the size of the share capital in H. Lundbeck A/S as per
the end of a month where changes therein have occurred. 

Referring to Corporate Release no 560 dated 21 May 2015, please find below a
statement regarding the total number of voting rights and share capital in H.
Lundbeck A/S as per 31 May 2015. 

             Number of shares  Nominal value  Number of votes
        (nominal value DKK 5)          (DKK)                 
-------------------------------------------------------------
Shares            196,616,031    983,080,155      196,616,031
-------------------------------------------------------------


Lundbeck contacts



Investors:                          Media:                   
                                                             
Palle Holm Olesen                   Mads Kronborg            
Vice President, Investor Relations  Director, Media Relations
palo@lundbeck.com                   mavk@lundbeck.com        
+45 36 43 24 26                     +45 36 43 30 00          
                                                             

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our key areas of focus are alcohol
dependence, Alzheimer's disease, bipolar disorder, depression/anxiety,
epilepsy, Huntington's disease, Parkinson's disease, schizophrenia and
symptomatic neurogenic orthostatic hypotension (NOH). 

An estimated 700 million people worldwide are living with brain disease and far
too many suffer due to inadequate treatment, discrimination, a reduced number
of working days, early retirement and other unnecessary consequences. Every
day, we strive for improved treatment and a better life for people living with
brain disease - we call this Progress in Mind. 

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales.
Our pipeline consists of several late-stage development programs and our
products are available in more 100 countries. We have research centers in
China, Denmark and the United States and production facilities in China,
Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5
billion in 2014 (EUR 1.8 billion; USD 2.4 billion). 

Lundbeck's shares are listed on the stock exchange in Copenhagen under the
symbol 'LUN'. Lundbeck has a sponsored Level 1 ADR program listed in the US
(OTC) under the symbol 'HLUYY'. 

For additional information, we encourage you to visit our corporate site
www.lundbeck.com.
News Source: NASDAQ OMX



---------------------------------------------------------------------

2015-06-02 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English          
Company:     H. Lundbeck A/S  
 
 
             Denmark          
ISIN:        DK0010287234     
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
364277 2015-06-02